Search - tctmd.com

Displaying 1 - 20 of 216

Sort: Relevancy | Date

News Conference News ACC 2026

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Yael L. Maxwell

April 01, 2026

Presentation ACC 2026

Essence-TIMI 73b CCTA Trial: Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis

Presenter: Nicholas Marston

March 30, 2026

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

Presentation ACC 2026

Evolocumab in Patients without Known Atherosclerosis and with Diabetes: Secondary Analysis from VESALIUS-CV

Presenter: Nicholas Marston

March 28, 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

News Daily News

Ultraprocessed Food Again Linked to Higher CVD Risk: MESA

Michael O'Riordan

March 17, 2026

News Daily News

Better LDL Control After STEMI Means Less Neoatherosclerosis

Yael L. Maxwell

December 23, 2025

News Daily News

Risk Calculators Miss Many Patients Who Present With First MI

Michael O'Riordan

November 21, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Daily News

Risk Factors Present in Nearly All Patients Who Develop CVD

Michael O'Riordan

October 02, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Daily News

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Yael L. Maxwell

August 18, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

Genetic Risk Score for Endothelial Cell Dysfunction Identifies Patients at Risk

News Daily News

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

Michael O'Riordan

February 27, 2025

News Daily News

Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE

Yael L. Maxwell

February 14, 2025

News Daily News

Athletes’ Hearts Also Require Careful Scrutiny, New Review Suggests

Yael L. Maxwell

January 17, 2025

News Daily News

Higher Lp(a) Indicates Greater Chance of Stenosis on CCTA in Patients With Chest Pain

Yael L. Maxwell

January 13, 2025

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Caitlin E. Cox

November 21, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

Advertisement

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Essence-TIMI 73b CCTA Trial: Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Evolocumab in Patients without Known Atherosclerosis and with Diabetes: Secondary Analysis from VESALIUS-CV

What’s Going to Be Hot at ACC 2026

Ultraprocessed Food Again Linked to Higher CVD Risk: MESA

Better LDL Control After STEMI Means Less Neoatherosclerosis

Risk Calculators Miss Many Patients Who Present With First MI

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Risk Factors Present in Nearly All Patients Who Develop CVD

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE

Athletes’ Hearts Also Require Careful Scrutiny, New Review Suggests

Higher Lp(a) Indicates Greater Chance of Stenosis on CCTA in Patients With Chest Pain

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content